Statin immunomodulation and thyroid cancer
2014; Wiley; Volume: 82; Issue: 4 Linguagem: Inglês
10.1111/cen.12600
ISSN1365-2265
AutoresLuca Mascitelli, Larry B. Goldstein,
Tópico(s)Ubiquitin and proteasome pathways
ResumoClinical EndocrinologyVolume 82, Issue 4 p. 620-620 Letter to the Editor Statin immunomodulation and thyroid cancer Luca Mascitelli, Luca Mascitelli [email protected] Medical Service, Comando Brigata Alpina “Julia”/Multinational Land Force, Udine, ItalySearch for more papers by this authorMark R. Goldstein, Mark R. Goldstein NCH Physician Group, Naples, FL, USASearch for more papers by this author Luca Mascitelli, Luca Mascitelli [email protected] Medical Service, Comando Brigata Alpina “Julia”/Multinational Land Force, Udine, ItalySearch for more papers by this authorMark R. Goldstein, Mark R. Goldstein NCH Physician Group, Naples, FL, USASearch for more papers by this author First published: 01 September 2014 https://doi.org/10.1111/cen.12600Citations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Hung, S.H., Lin, H.C. & Chung, S.D. (2014) Statin use and thyroid cancer: a population-based case-control study. Clinical Endocrinology, doi: 10.1111/cen.12570. [Epub ahead of print]. 2Imai, H., Saio, M., Nonaka, K. et al. (2007) Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Science, 98, 416– 423. 3Gogali, F., Paterakis, G., Rassidakis, G.Z. et al. (2012) Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. Journal of Clinical Endocrinology and Metabolism, 97, 1474– 1482. 4Ugolini, C., Elisei, R., Proietti, A. et al. (2014) FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment. Thyroid, 24, 339– 346. 5Goldstein, M.R., Mascitelli, L. & Pezzetta, F. (2009) The double-edged sword of statin immunomodulation. International Journal of Cardiology, 135, 128– 130. 6Mausner-Fainberg, K., Luboshits, G., Mor, A. et al. (2008) The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis, 197, 829– 839. Citing Literature Volume82, Issue4April 2015Pages 620-620 ReferencesRelatedInformation
Referência(s)